Authors:
Ly TT; Nicholas JA; Retterath A; Davis EA; Jones TW
Authors notes:
Diabetes Care. 2012;35(7):1462-1465
Keywords:
Diabetes, Blood Glucose profiles, Pump-therapy, Insulin suspension
Abstract
The advent of sensor-augmented pump therapy with a low-glucose suspend (LGS) function (Medtronic Paradigm Veo System), allowing insulin to be automatically suspended for up to 2 h when sensor glucose falls below a preset threshold, has the potential to reduce the duration of hypoglycemia.
In this article, we analyzed blood glucose profiles following a full 2-h insulin suspension activated by the LGS function, as well as examined different patterns of use among patients.
There were 3,128 LGS events during the 2,493 days evaluated.
The median duration was 11.2 min, and 36% of events occurred overnight. There were 126 full 2-h suspend events that occurred overnight with no patient response, occurring before 3:00 A.M.
There were no episodes of severe hypoglycemia or diabetic ketoacidosis.
Analyses of sensor glucose patterns following insulin suspension activated by LGS suggest that this technology is safe and unlikely to be associated with adverse outcomes.